Pancreatic Neuroendocrine Tumor Associated with Pancreatic Adenocarcinoma: A Case Report and Review of the Literature

Main Article Content

Asmar Mohamed
Ettaoussi Abdelhak
Saâd Rifki Jai
Driss Erguibi
Rachid Boufettal
Farid Chehab

Abstract

Pancreatic adenocarcinoma (PAC) is a high mortality cancer. Age, nicotine exposure, obesity, old-onset type 2 diabetes and chronic pancreatitis are identified risk factors for PAC. The Peutz-Jeghers Syndrome, Atypical Familial Syndrome of Multiple Moles and Melanomas (AFSMMM), Hereditary Ovarian and Breast Cancer, HNPCC and Familial Adenomatous Polyposis are the major genetic syndromes at high risk for pancreatic cancer. Neuroendocrine tumours (NETs) are defined by the expression of structural proteins and hormonal products common to neurons and endocrine cells. There is no identified risk factor for pancreatic NETs other than genetic predisposition syndromes (multiple endocrine neoplasia type 1 [MEN1], von Hippel-Lindau syndrome, tuberous sclerosis [TBS]). In this article we present a case of pancreatic neuroendocrine tumor associated with pancreatic adenocarcinoma and we discuss in light of the data in the literature, the risk factors that expose to both types of pancreatic tumors).

Keywords:
Risk factors, Pancreatic Adenocarcinoma (PAC), neuroendocrine carcinoma of the pancreas, multiple endocrine neoplasia [NEM1].

Article Details

How to Cite
Mohamed, A., Abdelhak, E., Jai, S. R., Erguibi, D., Boufettal, R., & Chehab, F. (2020). Pancreatic Neuroendocrine Tumor Associated with Pancreatic Adenocarcinoma: A Case Report and Review of the Literature. Asian Journal of Research and Reports in Gastroenterology, 4(1), 14-18. Retrieved from https://journalajrrga.com/index.php/AJRRGA/article/view/30124
Section
Case Study

References

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371: 569-78.

Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-83.

Jorgensen MT, Mortensen MB, Gerdes AM, Schaffalitzky de Muckadell OB. Familial pancreatic cancer. Scand J Gastroenterol. 2008;43:387-97.

Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, et al. Familial pancreatic cancer: Concept, management and issues. World Journal of Gastroenterology. 2017;23(6): 935-948.

Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3: e516.

Gilgenkrantz S. Cancer familial du pancréas et gène palladin. Un nouveau regard sur le processus cancéreux. Med Sci (Paris). 2007;23:232-4.

Rebours V, Boutron-Ruault MC, Schnee M, Ferec C, Maire F, Hammel P, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: A national exhaustive series. AmJ Gastroenterol. 2008;103:111-9.

Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007;56:601-5.

Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56:1460-9.

de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer. 2016;23(10):T57-67.

Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: A systematic review and meta-analysis. Ann Oncol 2016; 27:68–81. DOI: 10.1093/annonc/mdv505

Rindi G, Klimstra DS, Arnold R, Klöppel G, Bosman FT, Komminoth P, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC. 2010;13–4.

Zerbi A, Falconi M, Rindi G. Clinicopathological features of pancreatic endocrine tumors: A prospective multi-center study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105: 1421–9.

de Mestier L, Deguelte-Lardiere S, Brixi H, Kianmanesh R, Cadiot G. [Digestive neuroendocrine tumors]. Rev Med Internet. 2016;37:551–60. DOI : 10.1016/j.revmed.2016.01.012